Hualan Biological Vaccine Inc. (SHE:301207)

Hualan Biological Vaccine Revenue

Hualan Biological Vaccine had revenue of 17.61M CNY in the quarter ending June 30, 2026, a decrease of -50.64%. This brings the company's total for the last twelve months to 1.19B, up 3.01% year-over-year. In the year 2025, Hualan Biological Vaccine had annual revenue of 1.20B with 6.62% growth. That makes Hualan Biological Vaccine the 18,301st largest company in the world by revenue and 3,329th in China.

• Revenue (ttm): 1.19B
• Revenue Growth: +3.01%
• P/S Ratio: 9.13
• Revenue / Employee: 1.68M
• Employees: 708
• Market Cap: 10.33B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Flu vaccine 1.20B 99.7%
• Others 3.26M 0.3%

By Geography

Chart

• China 1.20B 99.9%
• Foreign 1.58M 0.1%

Fiscal year ended Dec 31, 2025 See the full Hualan Biological Vaccine breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.20B	74.69M	6.62%
Dec 31, 2024	1.13B	-1.28B	-53.21%
Dec 31, 2023	2.41B	584.79M	32.03%
Jan 1, 2023	1.83B	-4.17M	-0.23%
Jan 1, 2022	1.83B	-596.52M	-24.59%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 20, 2026

Data Sources Report a data error